Information  X 
Enter a valid email address

Clinigen Group plc (CLIN)


Thursday 30 September, 2021

Clinigen Group plc

Annual Financial Report

RNS Number : 4580N
Clinigen Group plc
30 September 2021

30th September 2021







Posting of Annual Report and Accounts and
arrangements for AGM


Clinigen Group plc (AIM: CLIN, 'Clinigen' or 'the Group'), the global pharmaceutical Services and Products company, announces that its Annual Report and Accounts for the year ended 30 June 2021 is now available on the Group's website at  and confirms the date and location for its Annual General Meeting ('AGM').


The Group will hold its AGM on Wednesday, 24 November 2021 at 10.00am GMT at 85 Gresham Street, London EC2V 7NQ. A hard copy of the Annual Report will be mailed to shareholders later today.


The arrangements for the AGM are as follows:


Shareholders are able to attend the AGM in person this year. Those intending to attend the AGM are asked to register their intention by emailing [email protected] with 'AGM 2021 - attendance' in the heading. However, at the time of writing it is uncertain what regulations or public health guidance may be in place at the time of the AGM and therefore the Board strongly encourages shareholders to submit a proxy vote in advance of the AGM and to appoint the Chairman of the meeting as their proxy, rather than a named person who, if circumstances change, may not be able to attend the meeting. Please refer to the instructions in the Form of Proxy, which has been distributed with the Annual Report and Accounts. We will continue to closely monitor any developments in public health guidance and legislation issued by the UK Government in relation to Covid-19. Should it become necessary or appropriate to revise the current arrangements for the AGM, details of any such changes will be made available on our website and via a regulatory information service announcement.

The Company will upload a presentation to shareholders by the Chief Executive Officer, Shaun Chilton, on the business of the Clinigen Group and its performance over the last 12 months to . The presentation will be uploaded no later than 12 November 2021. The AGM will focus on the formal business of the meeting as set out in the Notice of AGM.

Should any shareholder have questions they wish to ask, they should email [email protected] with 'AGM 2021' in the heading. The Company will collate the answers to the questions received and upload them to shareholder-services/agm following the publication of the results of the AGM or, if more appropriate, reply to the questioner directly . Questions must be received no later than 10.00 a.m. on Monday, 22 November 2021.

- Ends -






Contact details

Clinigen Group plc

+44 (0) 1283 495010

Rob Fox, VP Investor Relations and Corporate Development

[email protected]

Numis Securities Limited - Nominated Adviser & Joint Broker

Tel: +44 (0) 20 7260 1000

James Black / Garry Levin / Freddie Barnfield

[email protected]


RBC Capital Markets - Joint Broker

Tel: +44 (0) 20 7653 4000

Marcus Jackson / Elliot Thomas

Consilium Strategic Communications

Mary-Jane Elliott / Matthew Cole / Jessica Hodgson  

Tel: +44 (0) 20 3709 5700 [email protected]




Notes to Editors


About Clinigen Group

Clinigen Group plc (AIM: CLIN) is a global, specialist pharmaceutical services and products platform focused on providing ethical access to medicines. Its mission is to deliver the right medicine to the right patient at the right time. The Group operates from sites in North America, Europe, Africa and the Asia Pacific.

Clinigen has more than 1,000 employees across five continents in 14 countries, with supply and distribution hubs and operational centres of excellence in key long-term growth regions. The Group works with 34 of the top 50 pharmaceutical companies; interacting with over 5,000 hospitals across more than 120 countries.

For more information on Clinigen, please visit  

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact [email protected] or visit

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.

a d v e r t i s e m e n t